Actively Recruiting
Phase 12a Open-Label Study of BI-1808 Alone and With Pembrolizumab and Paclitaxel in Advanced Malignancies
Led by BioInvent International AB · Updated on 2026-09-18
250
Participants Needed
25
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying BI-1808, a monoclonal antibody targeting TNFR2, to evaluate its safety, tolerability, and dosing in adults with advanced malignancies such as advanced solid tumors and T-cell lymphoma whose disease has progressed after standard treatments. This first-in-human Phase 12a trial aims to find the maximum tolerated dose and recommend doses for future studies. The study includes dose escalation and expansion phases to better understand the treatments effects. Participants will receive BI-1808 as a single agent or combined with pembrolizumab, and in some cases, with pembrolizumab plus paclitaxel. Treatments are given by intravenous infusion every three weeks. The study consists of two phases Phase 1, which has dose escalation parts for BI-1808 alone and with pembrolizumab, and Phase 2a, which expands on these treatments and adds a combination with paclitaxel to further assess safety and dosing. Throughout the study, participants undergo regular monitoring for side effects, drug levels in the blood, immune responses, and tumor activity using standard criteria. Researchers will track adverse events for up to two years and evaluate tumor response, progression-free survival, and drug effects. Participants will have scheduled visits for infusions and assessments to support safety and effectiveness evaluations during treatment and follow-up.
CONDITIONS
Brief Title
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Research Team
S
Susanne Gertsson
M
Mona Welschof, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here